IDSA GUIDELINES Bundle (free trial)

Aspergillosis 2016

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/57608

Contents of this Issue

Navigation

Page 18 of 23

18 Table 1. Summary of Recommendations for the Treatment of Aspergillosis (cont'd) Condition Therapy Invasive syndromes of Aspergillus Primary Alternative Comments Chronic cavitary pulmonary aspergillosis Similar to IPA Similar to IPA • Innate immune defects demonstrated in most of these patients. • Long-term therapy may be needed. • Surgical resection may lead to significant complications. • Anecdotal response to IFN-γ. • Tranexamic acid may be helpful in management of hemoptysis. Allergic Syndromes of Aspergillosis Primary Alternative Comments ABPA Itraconazole Oral voriconazole (200 mg PO every 12 h) or posaconazole (dosage depends on formulation) Corticosteroids are a cornerstone of therapy for exacerbations; itraconazole has a demonstrable corticosteroid- sparing effect Allergic rhinosinusitis caused by Aspergillus Polypectomy and sinus washout with intranasal corticosteroids Antifungal therapy reserved for refractory or relapsing cases

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Aspergillosis 2016